Study ended early - who's the winner? Zetia or Niaspan? Could New Jersey lose its pharma edge? BiogenIdec gets a fast track - Biogen Idec Inc., a Cambridge company known for its multiple sclerosis …
Today’s Top Three in Pharma 060409
OK, so it's a "baker's three" (8) today. Makes up for yesterday's zero...! Patent-holder urges FDA to NOT approve prasugrel (from Lilly/Daiichi Sankyo). Novartis getting cold feet at the Alcon …
Today’s Top Three in Pharma 021309
Promising no more: drug candidates fail - ViroPharma lost more than half its value in Nasdaq trading after experimental drug maribavir failed in tests on patients receiving bone-marrow transplants. …
Today’s Top Three in Pharma 021209
Just got back from the ePharma Summit in Philadelphia and it's going to take a couple days to digest, catch up, write up, etc. But here are a few news items for your Thursday: Two more pharma …
Today’s Top Three in Pharma 020409
Finally! New anti-clotting drug prasugrel (Effient) is given a thumbs up by advisory committee! Great news for Daiichi Sankyo and Eli Lilly. King Pharmaceuticals the latest to announce major layoffs …
Training Need: Curriculum Development/Facilitation
You have a need to pull together a bunch of scattered training materials/workshops into a comprehensive curriculum. Maybe you also need a vendor/partner who can not only head up design and …
Continue Reading about Training Need: Curriculum Development/Facilitation →